Identifying amyloid pathology–related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study

Article English OPEN
Leung, Yuk Yee; Toledo, Jon B.; Nefedov, Alexey; Polikar, Robi; Raghavan, Nandini; Xie, Sharon X.; Farnum, Michael; Schultz, Tim; Baek, Young; Van Deerlin, Vivianna M.; Hu, William T.; Holtzman, David M.; Fagan, Anne M.; Perrin, Richard J.; Grossman, Murray; Soares, Holly D.; Kling, Mitchel A.; Mailman, Matthew; Arnold, Steven E.; Narayan, Vaibhav A.; Lee, Virginia M-Y.; Shaw, Leslie M.; Baker, David; Wittenberg, Gayle M.; Trojanowski, John Q.; Wang, Li-San;
(2015)
  • Publisher: Elsevier BV
  • Journal: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring,volume 1,issue 3,pages339-348 (issn: 2352-8729, eissn: 2352-8729)
  • Related identifiers: pmc: PMC4672388, doi: 10.1016/j.dadm.2015.06.008
  • Subject: Alzheimer's disease | Biomarkers | Cerebrospinal fluid | Dementia | Cognitive impairment | CSF Biomarkers | Amyloid beta

Introduction The dynamic range of cerebrospinal fluid (CSF) amyloid β (Aβ1–42) measurement does not parallel to cognitive changes in Alzheimer's disease (AD) and cognitively normal (CN) subjects across different studies. Therefore, identifying novel proteins to characte... View more